|Security||LMB / Limbach Holdings, Inc. (53263P105)|
|President and CEO||Bacon Charles A. III|
|Industry||Construction Special Trade Contractors|
|Institutional Shares||2,585,021 - 34.05%|
|Common Shares Outstanding||7,590,778 shares (as of 2018-06-30)|
|Institutional Value||$ 30,040,000 USD|
TFSC / 1347 Capital Corp.|
LMBH / Limbach Holdings, Inc
LMBHW / Limbach Holdings, Inc
Institutional Stock Ownership and Shareholders
Limbach Holdings, Inc. (NASDAQ:LMB) has 27 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,585,021 shares.
Largest shareholders include
State of New Jersey Common Pension Fund D, Dimensional Fund Advisors Lp, Perritt Capital Management Inc, Arbor Wealth Management, LLC, Acuitas Investments, Llc, Legato Capital Management LLC, Argent Capital Management Llc, Vanguard Group Inc, Pacific View Asset Management, Llc, and Bridgeway Capital Management Inc.
Limbach Holdings, Inc. (NASDAQ:LMB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|State of New Jersey Common Pension Fund D||644,000||644,000||0.00||7,973||7,612||-4.53|
|Pacific View Asset Management, Llc||90,860||1,074|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||2,716||760||-72.02||33||9||-72.73|
|NJ State Employees Deferred Compensation Plan||43,000||43,000||0.00||532||508||-4.51|
|Acuitas Investments, Llc||50,060||163,699||227.01||620||1,935||212.10|
|Steward Partners Investment Advisory, Llc||9,724||11,755||20.89||118||139||17.80|
|ESSEX INVESTMENT MANAGEMENT CO LLC||18,394||17,851||-2.95||225||211||-6.22|
|Advisor Group, Inc.||230||230||0.00||3||3||0.00|
|VANGUARD GROUP INC||108,444||109,290||0.78||1,342||1,291||-3.80|
|Renaissance Technologies LLC||13,500||165|
|PERRITT CAPITAL MANAGEMENT INC||285,050||280,050||-1.75||3,572||3,310||-7.33|
|UBS Group AG||4,763||5,134||7.79||58||60||3.45|
|Tower Research Capital LLC (TRC)||8,061||0||-100.00||99||0||-100.00|
|LPL Financial LLC||42,540||42,540||0.00||520||503||-3.27|
|SILVER CAPITAL MANAGEMENT LLC||14,236||38,686||171.75||197||189||-4.06|
|New Jersey Better Educational Savings Trust||46,000||44,000||-4.35||569||520||-8.61|
|DEUTSCHE BANK AG\||11,100||13,300||19.82||135||157||16.30|
|JP Morgan Chase & Co||6,068||72|
|Legato Capital Management LLC||140,005||140,005||0.00||1,711||1,655||-3.27|
|ARGENT CAPITAL MANAGEMENT LLC||111,180||111,180||0.00||1,359||1,314||-3.31|
|Mesirow Financial Investment Management, Inc.||37,093||21,199||-42.85||453||251||-44.59|
|CWA Asset Management Group, LLC||11,380||10,380||-8.79||139||123||-11.51|
|Arbor Wealth Management, LLC||213,553||211,808||-0.82||2,695||2,253||-16.40|
|BRIDGEWAY CAPITAL MANAGEMENT INC||54,000||638|
|MACQUARIE GROUP LTD||17,906||2,706||-84.89||219||32||-85.39|
|DIMENSIONAL FUND ADVISORS LP||458,904||495,935||8.07||5,681||5,862||3.19|
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
Limbach Holdings, Inc. (NASDAQ:LMB) Limbach - Dunbar Acquisition Conference Call September 20, 2018 8:30 AM ET (0-1)
The following slide deck was published by Limbach Holdings, Inc in conjunction with their 2018 Q2 earnings call.
Greetings and welcome to Limbach Holdings Q2 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
Limbach Holdings, Inc. (NASDAQ:LMB) Q1 2018 Results Earnings Conference Call May 16, 2018 9:00 AM ET (1-1)
The following slide deck was published by Limbach Holdings, Inc in conjunction with their 2018 Q1 earnings call. (1-0)
as of ET